New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Lawrence W Jr, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D. Adult soft tissue sarcomas: a pattern of care survey of the american college of surgeons. Ann. Surg.205(4), 349–359 (1987).
   PubMed Web of Science ®Google Scholar
• Chbani L, Guillou L, Terrier P et al. Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the french sarcoma group. Am. J. Clin. Pathol.131(2), 222–227 (2009).
   PubMed Web of Science ®Google Scholar
• Toro JR, Travis LB, Wu HJ et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int. J. Cancer119(12), 2922–2930 (2006).
   PubMed Web of Science ®Google Scholar
• Nakayama R, Nemoto T, Takahashi H et al. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod. Pathol.20(7), 749–759 (2007)
   PubMed Web of Science ®Google Scholar
• Froehner M, Wirth MP. Etiologic factors in soft tissue sarcomas. Onkologie24(2), 139–142 (2001).
   PubMedGoogle Scholar
• Neuhaus SJ, Pinnock N, Giblin V et al. Treatment and outcome of radiation-induced soft-tissue sarcomas at a specialist institution. Eur. J Surg. Oncol.35(6), 654–659 (2009).
   PubMed Web of Science ®Google Scholar
• Krishnan B, Khanna G, Clohisy D. Gene translocations in musculoskeletal neoplasms. Clin. Orthop. Relat. Res.466(9), 2131–2146 (2008).
   PubMed Web of Science ®Google Scholar
• Gonin-Laurent N, Hadj-Hamou NS, Vogt N et al. RB1 and TP53 pathways in radiation-induced sarcomas. Oncogene26(41), 6106–6112 (2007).
   PubMed Web of Science ®Google Scholar
• Tawbi H, Thomas D, Lucas DR et al. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist13(4), 459–466 (2008).
   PubMed Web of Science ®Google Scholar
• Dobashi Y, Suzuki S, Sugawara H, Ooi A. Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors. Hum. Pathol.38, 914–925 (2007).
   PubMed Web of Science ®Google Scholar
• de Alava E, Kawai A, Healey JH et al. EWS–FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma. J Clin. Oncol.16(4), 1248–1255 (1998).
   PubMed Web of Science ®Google Scholar
• Canter RJ, Qin LX, Maki RG, Brennan MF, Ladanyi M, Singer SA. Synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin. Cancer Res.14(24), 8191–8197 (2008).
   PubMed Web of Science ®Google Scholar
• Ladanyi M, Antonescu CR, Leung DH et al. Impact of SYT–SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res.62(1), 135–140 (2002).
   PubMed Web of Science ®Google Scholar
• Guillou L, Benhattar J, Bonichon F et al. Histologic grade, but not SYT–SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J. Clin. Oncol.22(20), 4040–4050 (2004).
   PubMed Web of Science ®Google Scholar
• Schuetze SM, Baker LH, Benjamin RS, Canetta R. Selection of response criteria for clinical trials of sarcoma treatment. Oncologist13(Suppl. 2), 32–40 (2008)
   PubMed Web of Science ®Google Scholar
• Jaffe CC. Response assessment in clinical trials: implications for sarcoma clinical trial design. Oncologist13(Suppl. 2), 14–18 (2008).
   PubMed Web of Science ®Google Scholar
• Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist13(Suppl. 2), 4–7 (2008).
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, Verweij J, Judson I et al. Progression-free rate as the principal end-point for Phase II trials in soft-tissue sarcomas. Eur. J Cancer38(4), 543–549 (2002).
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline. Eur. J. Cancer45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• Yang JC, Chang AE, Baker AR et al. A randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J. Clin. Oncol.16(1), 197–203 (1998).
   PubMed Web of Science ®Google Scholar
• Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol.19(Suppl. 2), 89–93 (2008).
   Google Scholar
• Krempien R, Roeder F, Oertel S et al. Intraoperative electron-beam therapy for primary and recurrent retroperitoneal soft-tissue sarcoma. Int. J. Radiat. Oncol. Biol. Phys.65(3), 773–779 (2006).
   PubMed Web of Science ®Google Scholar
• Pisters P. Staging and prognosis. In: American Cancer Society Atlas of Clinical Oncology: Soft Tissue Sarcomas. Pollock RE (Ed.). Decker, Inc, Hamiliton, Ontario, Canada 80–88 (2002).
   Google Scholar
• Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist10(10), 833–841 (2005).
   PubMed Web of Science ®Google Scholar
• Grobmyer SR, Maki RG, Demetri GD et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann. Oncol.15(11), 1667–1672 (2004).
   PubMed Web of Science ®Google Scholar
• Gortzak E, Azzarelli A, Buesa J et al. A randomised Phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur. J. Cancer37(9), 1096–1103 (2001).
   PubMed Web of Science ®Google Scholar
• Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer113(3), 573–581 (2008).
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Van Glabbeke M, Woll PJ et al. The end of adjuvant chemotherapy era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma: pooled analysis of the two STBSG-EORTC Phase III clinical trials. J. Clin. Oncol.26(15s), 559s (2008).
   Google Scholar
• Jelic S, Kovcin V, Milanovic N et al. Randomised study of high-dose epirubicin versus high-dose epirubicin–cisplatin chemotherapy for advanced soft tissue sarcoma. Eur. J Cancer33(2), 220–225 (1997).
   PubMed Web of Science ®Google Scholar
• Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a Phase II study. J. Clin. Oncol.16(4), 1438–1443 (1998).
   PubMed Web of Science ®Google Scholar
• Bui NB, Demaille MC, Chevreau C et al. qMAID vs MAID + 25 % in adults with advanced soft tissue sarcoma (STS): first results of a randomized study of the FNCLCC sarcoma Group. Proc. Am. Soc. Clin. Oncol.17, 517a (1998).
   Web of Science ®Google Scholar
• Nielsen OS, Judson I, van Hoesel Q et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas: a multicentre Phase II study of the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer36(1), 61–67 (2000).
   PubMed Web of Science ®Google Scholar
• Frustaci S, Buonadonna A, Romanini A et al. Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas: a study of the Italian group on rare tumors. Tumori85(4), 229–233 (1999).
   PubMed Web of Science ®Google Scholar
• Demetri GD. Major developments in the understanding and treatment of soft-tissue sarcomas in adults. Curr. Opin. Oncol.10(4), 343–347 (1998).
   PubMedGoogle Scholar
• Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M. Sarcoma disease site group of cancer care Ontario’s program in evidence-based care dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review. Cancer112(6), 1197–1205 (2008).
   PubMed Web of Science ®Google Scholar
• Kasper B, Dietrich S, Mechtersheimer G, Ho AD, Egerer G. Large institutional experience with dose-intensive chemotherapy and stem cell support in the management of sarcoma patients. Oncology73(1–2), 58–64 (2007).
   PubMed Web of Science ®Google Scholar
• Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J. Clin. Oncol.20(12), 2824–2831 (2002).
   PubMed Web of Science ®Google Scholar
• Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group Phase II trial. Gynecol. Oncol.109(3), 329–334 (2008).
   PubMed Web of Science ®Google Scholar
• Penel N, Bui BN, Bay JO et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J. Clin. Oncol.26(32), 5269–5274 (2008).
   PubMed Web of Science ®Google Scholar
• Schlemmer M, Reichardt P, Verweij J et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer44(16), 2433–2436 (2008).
   PubMed Web of Science ®Google Scholar
• Maki RG, Wathen JK, Patel SR et al. Randomized Phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft-tissue sarcomas. J. Clin. Oncol.25(19), 2755–2763 (2007).
   PubMed Web of Science ®Google Scholar
• Duffaud F, Bui BN, Penel N et al. A FNCLCC french sarcoma group-GETO multicenter randomized Phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). J. Clin. Oncol.26(15s), (2008).
   Google Scholar
• Hartmann JT, Mayer F, Schleicher J et al. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter Phase II study of the german sarcoma group. Cancer110(4), 861–866 (2007).
   PubMed Web of Science ®Google Scholar
• Hartmann JT, Oechsle K, Mayer F, Kanz L, Bokemeyer C. Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res.23(2C), 1899–1901 (2003).
   PubMed Web of Science ®Google Scholar
• Kasper B, Ho AD, Egerer G. A new therapeutic approach in patients with advanced sarcoma. Int. J. Clin. Oncol.10(6), 438–440 (2005).
   PubMedGoogle Scholar
• Verweij J. Ecteinascidin-743 (ET-743): Early test or effective treatment in soft tissue sarcomas? J. Clin. Oncol.23(24), 5420–5423 (2005).
   PubMed Web of Science ®Google Scholar
• Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol.8(7), 595–602 (2007).
   PubMed Web of Science ®Google Scholar
• Blay JY, von Mehren M, Samuels BL et al. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin. Cancer Res.14(20), 6656–6662 (2008).
   PubMed Web of Science ®Google Scholar
• Sessa C, Perotti A, Noberasco C et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur. J. Cancer45(7), 1153–1161 (2009).
   PubMed Web of Science ®Google Scholar
• Leahy M, Ray-Coquard I, Verweij J et al. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a Phase II study from the european organisation for research and treatment of cancer soft tissue and bone sarcoma group. Eur. J. Cancer43(2), 308–315 (2007).
   PubMed Web of Science ®Google Scholar
• Yoon SS, Segal NH, Park PJ et al. Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J. Surg. Res.135(2), 282–290 (2006).
   PubMed Web of Science ®Google Scholar
• Yoon SS, Segal NH, Olshen AB, Brennan MF, Singer S. Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann. Oncol.15(8), 1261–1266 (2004).
   PubMed Web of Science ®Google Scholar
• Yi -Shin Kuo D, Timmins P, Blank SV et al. Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium. Gynecol. Oncol.100(1), 160–165 (2006).
   PubMed Web of Science ®Google Scholar
• D’Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft tissue sarcomas. J. Clin. Oncol.23(28), 7135–7142 (2005).
   PubMed Web of Science ®Google Scholar
• Maki RG, Keohan ML, Undevia M et al. Updated results of a Phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study 7060. J. Clin. Oncol.26(15s), 560s (2008).
   Google Scholar
• Keohan ML, Morgan JA, D’Adamo DR et al. Continuous daily dosing (CCD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: results of a Phase II trial. J. Clin. Oncol.26(15s), 501s (2008).
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Papai Z, Le Cesne A et al. Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS). EORTC 62043. Proc. Am. Soc. Clin. Oncol.25, 18s (2007).
   Google Scholar
• Ren W, Korchin B, Zhu QS et al. Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo.Clin. Cancer Res.14(9), 2785–2795 (2008).
   PubMed Web of Science ®Google Scholar
• Keizman D, Issakov J, Meller I et al. Expression and significance of EGFR in malignant peripheral nerve sheath tumor. J. Neurooncol. DOI 10.1007/s11060-009-9862-z (2009) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Le Cesne A, Whelan JS et al. A Phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist13(4), 467–473 (2008).
   PubMed Web of Science ®Google Scholar
• Ren W, Korchin B, Lahat G et al. Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. Clin. Cancer Res.14(17), 5466–5475 (2008).
   PubMed Web of Science ®Google Scholar
• Pelmus M, Guillou L, Hostein I, Sierankowski G, Lussan C, Coindre JM. Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYTSSX)-positive cases. Am. J. Surg. Pathol.26(11), 1434–1440 (2002).
   PubMed Web of Science ®Google Scholar
• Kaseta MK, Khaldi L, Gomatos IP et al. Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma. J. Surg. Oncol.97(3), 259–266 (2008).
   PubMed Web of Science ®Google Scholar
• Joyner DE, Albritton KH, Bastar JD, Randall RL. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line. J. Orthop. Res.24(6), 474–480 (2006).
   PubMed Web of Science ®Google Scholar
• Hernando E, Charytonowicz E, Dudas ME et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat. Med.13(6), 748–753 (2007).
   PubMed Web of Science ®Google Scholar
• Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist12(8), 1007–1018 (2007).
   PubMed Web of Science ®Google Scholar
• Chawla S, Tolcher A, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of Phase II trial. Proc. Am. Soc. Clin. Oncol.25, 18s (2007).
   Google Scholar
• Murphy JD, Spalding AC, Somnay YR, Markwart S, Ray ME, Hamstra DA. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin. Cancer Res.15(2), 589–596 (2009).
   PubMed Web of Science ®Google Scholar
• Misset JL, Gamelin E, Campone M et al. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Ann. Oncol.15(7), 1123–1129 (2004).
   PubMed Web of Science ®Google Scholar
• Hartmann JT, Bauer S, Schaedel S et al. A non-comparative Phase II study of pemetrexed in patients with pretreated soft tissue sarcoma: german sarcoma group/AIO 005. J. Clin. Oncol.26(15s) (2008).
   Google Scholar
• Morris DG, Bramwell VH, Turcotte R et al. A Phase II study of flavopiridol in patients with previously untreated advanced soft tissue sarcoma. Sarcoma2006, 64374(2006).
   PubMedGoogle Scholar
• D’Adamo DR, Scheu K, Singer S et al. A Phase I trial of doxorubicin and flavopiridol in soft tissue sarcoma. Proc. Am. Soc. Clin. Oncol.24, 18s (2006).
   Google Scholar
• Kutko MC, Glick RD, Butler LM et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.Clin. Cancer Res.9(15), 5749–5755 (2003).
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Tanaka K, Sakimura R et al. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res.28(3A), 1585–1591 (2008).
   PubMed Web of Science ®Google Scholar
• Kelly WK, O’Connor OA, Krug LM et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol.23(17), 3923–3931 (2005).
   PubMed Web of Science ®Google Scholar
• Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT. The insulin-like growth factor system and sarcomas. J. Pathol.217(4), 469–482 (2009).
   PubMed Web of Science ®Google Scholar
• Olmos D, Okuno S, Schuetze SM et al. Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma. J. Clin. Oncol.26(15s) (2008) (Abstract 10501).
   PubMed Web of Science ®Google Scholar
• Benz MR, Evilevitch V, Allen-Auerbach MS et al. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors, J. Nucl. Med.49(7), 1038–1046 (2008).
   PubMed Web of Science ®Google Scholar
• Folpe AL, Lyles RH, Sprouse JT et al. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin. Cancer Res.6(4), 1279–1287 (2000).
   PubMed Web of Science ®Google Scholar
• Völker T, Denecke T, Steffen I et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J. Clin. Oncol.25(34), 5435–5441 (2007).
   PubMed Web of Science ®Google Scholar
• Evilevitch V, Weber WA, Tap WD et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin. Cancer Res.14(3), 715–720 (2008).
   PubMed Web of Science ®Google Scholar
• Schuetze SM, Rubin BP, Vernon C et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer103(2), 339–348 (2005).
   PubMed Web of Science ®Google Scholar
• Lisle JW, Eary JF, O’Sullivan J, Conrad EU. Risk assessment based on FDG-PET imaging in patients with synovial sarcoma. Clin. Orthop. Relat. Res.467(6), 1605–1611 (2009).
   PubMed Web of Science ®Google Scholar
• Brenner W, Conrad EU, Eary JF. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur. J. Nucl. Med. Mol. Imaging31, 189–195 (2004).
   PubMed Web of Science ®Google Scholar
• Brenner W, Eary JF, Hwang W, Vernon C, Conrad EU. Risk assessment in liposarcoma patients based on FDG PET imaging. Eur. J. Nucl. Med. Mol. Imaging33(11), 1290–1295 (2006).
   PubMed Web of Science ®Google Scholar
• Kasper B, Dietrich S, Dimitrakopoulou-Strauss A et al. Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography, Onkologie31(3), 107–112 (2008).
   PubMedGoogle Scholar
• Buck AK, Herrmann K, Büschenfelde CM et al. Imaging bone and soft tissue tumors with the proliferation marker [18F] fluorodeoxythymidine. Clin. Cancer Res.14(10), 2970–2977 (2008).
   PubMed Web of Science ®Google Scholar
• Baur A, Stäbler A, Wendtner CM et al. MR-imaging changes of musculoskeletal soft-tissue sarcomas associated with neoadjuvant chemotherapy and hyperthermia, Int. J. Hyperthermia19(4), 391–401 (2003).
   PubMed Web of Science ®Google Scholar
• Dudeck O, Zeile M, Pink D et al. Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J. Magn. Reson. Imaging27(5), 1109–1113 (2008).
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Collini P, Messina A et al. High-grade soft-tissue sarcomas: tumor response assessmen – pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology251(2), 447–456 (2009).
   PubMed Web of Science ®Google Scholar
• Song T, Shen J, Liang BL, Mai WW, Li Y, Guo HC. Retroperitoneal liposarcoma: MR characteristics and pathological correlative analysis. Abdom. Imaging32(5), 668–674 (2007).
   PubMedGoogle Scholar
• Lahat G, Madewell JE, Anaya DA et al. Computed tomography scan-driven selection of treatment for retroperitoneal liposarcoma histologic subtypes. Cancer115(5), 1081–1090 (2009).
   PubMed Web of Science ®Google Scholar